Supernus Pharmaceuticals (SUPN) Income from Continuing Operations (2011 - 2025)
Supernus Pharmaceuticals (SUPN) reported Income from Continuing Operations of 4134000.0 for Q4 2025, down 126.97% year-over-year from 15328000.0 in Q4 2024, and up 90.84% quarter-over-quarter from 45117000.0 in Q3 2025.
Supernus Pharmaceuticals (SUPN) Income from Continuing Operations (2011 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 15 years of Income from Continuing Operations data on file, last reported at 4134000.0 in Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 4134000.0, down 126.97% year-over-year; the trailing twelve-month figure through Dec 2025 was 38579000.0 (down 152.21% YoY), and the FY2025 annual result was 38550000.0, down 152.19% from the prior year.
- Income from Continuing Operations grew to 4134000.0 in Q4 2025 per SUPN's latest filing, from 45117000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 38543000.0 in Q3 2024 and troughed at 45117000.0 in Q3 2025.
- A 5-year average of 7532900.0 and a median of 6759000.0 in 2021 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 2494.95% in 2024, then sank 9637.9% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 2442000.0 in 2021, then surged by 944.55% to 25508000.0 in 2022, then plunged by 95.54% to 1137000.0 in 2023, then surged by 1248.11% to 15328000.0 in 2024, then tumbled by 126.97% to 4134000.0 in 2025.
- Business Quant data shows SUPN's Income from Continuing Operations at 4134000.0 in Q4 2025, 45117000.0 in Q3 2025, and 22499000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Supernus Pharmaceuticals | 2.57 Bn | 2.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.13 Mn |
| Sep 30, 2025 | -45.12 Mn |
| Jun 30, 2025 | 22.50 Mn |
| Mar 31, 2025 | -11.83 Mn |
| Dec 31, 2024 | 15.33 Mn |
| Sep 30, 2024 | 38.54 Mn |
| Jun 30, 2024 | 19.90 Mn |
| Mar 31, 2024 | 124,000.00 |
| Dec 31, 2023 | 1.14 Mn |
| Sep 30, 2023 | -16.01 Mn |
| Jun 30, 2023 | -831,000.00 |
| Mar 31, 2023 | 16.92 Mn |
| Dec 31, 2022 | 25.51 Mn |
| Sep 30, 2022 | 1.75 Mn |
| Jun 30, 2022 | 7.82 Mn |
| Mar 31, 2022 | 25.62 Mn |
| Dec 31, 2021 | 2.44 Mn |
| Sep 30, 2021 | 21.56 Mn |
| Jun 30, 2021 | 23.73 Mn |
| Mar 31, 2021 | 5.69 Mn |